Navigation Links
Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Date:5/1/2008

SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will release financial results for the three months ended March 31, 2008 after market close on Thursday, May 8, 2008.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, and David Ramsay, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, May 9, 2008, to provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 44830661.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Halozyme Contact

David A. Ramsay

Chief Financial Officer

(858) 704-8260

dramsay@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
2. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
4. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
5. Halozyme Therapeutics Amends Stockholder Rights Plan
6. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
7. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
8. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
9. United Therapeutics Reports First Quarter 2008 Financial Results
10. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
11. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Ames, Iowa (PRWEB) , ... December 08, 2016 , ... ... of asynchronous approvals for biotech crops. The authors focus on the economic effects in ... the global approval of new biotech crops and the resultant risk of low level ...
(Date:12/8/2016)... 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... and commercializing products to treat rare diseases where there ... will be hosting an Investor Webcast Event Friday, December ... of innate defense regulators (IDRs) as a new drug ... and the recently announced and published Phase 2 clinical ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
Breaking Biology News(10 mins):